Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Free Report) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 250,000 shares, a growth of 189.4% from the December 31st total of 86,400 shares. Based on an average daily volume of 3,070,000 shares, the short-interest ratio is currently 0.1 days. Currently, 5.8% of the shares of the stock are short sold.
Bio-Path Trading Down 0.5 %
BPTH stock traded down $0.00 during midday trading on Friday, reaching $0.81. 19,821 shares of the stock were exchanged, compared to its average volume of 168,118. Bio-Path has a 52 week low of $0.59 and a 52 week high of $9.99. The company has a fifty day moving average price of $0.89 and a 200 day moving average price of $1.07.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on shares of Bio-Path in a report on Wednesday. They set a “sell” rating on the stock.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Recommended Stories
- Five stocks we like better than Bio-Path
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Turnaround Stocks in the Early Innings With More Upside to Come
- The Risks of Owning Bonds
- Whirlpool: Buy This High-Yielding Value Before It Spins Higher
- Options Trading – Understanding Strike Price
- Commvault Systems: Share Price Primed to Vault Higher in 2025
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
